I am currently Professor of Cell and Molecular Biology at the University of Liverpool, which is actually my home town and continues to fascinate me. I have moved around though! After graduating in Chemistry and then a PhD in Biophysics in the UK, I did a post-doc at NIH studying membrane fusion mechanisms. I only really found my metier after moving for a second post-doc to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. This was a great environment to learn intricate cell biology techniques and remains a strong influence on how we approach our science. After establishing my own laboratory at Liverpool, we initially focused on the interplay between endosomal membrane trafficking and cell signaling. This ultimately led me to ubiquitin biology and to the deubiquitylases (DUBs). We laid down the concept that a balance between ubiquitin ligase and deubiquitylase activities determine receptor fate at the endosome. Since then we have been interested in identifying DUBs germane to oncology and neurodegeneration, with the aim of mechanistic understanding. In recent years, I have been pleased to work together with industry partners to drive the development of DUB inhibitors. I now look forward to working with Entact on the next phase of the DUB translational story — harnessing rather than inhibiting their activity.
Want to work with Michael?
See our latest job openingsSee what Michael and their colleagues have been up to:
06/23/2026 Press Releases
Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors
A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced proximity therapeutics. Houston's deep experience with protein degraders will be invaluable to supporting Entact’s development of ENTAC™ medicines, which leverage the same un...
02/08/2026 Publications
Targeted recruitment of USP15 enhances CTLA4 surface levels and restricts its degradation
09/17/2024 Press Releases
Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer
Veteran drug developer and R&D leader with three decades of pharmaceutical and biotech experience to oversee development of targeted protein enhancement modality Watertown, MA, September 17, 2024 – Entact Bio, a company committed to improving the lives of patients by developing precision medicines that enhance the fu...
05/29/2024 Press Releases
Entact Bio Appoints Michael Gutch, Ph.D., as Chief Operating Officer
Veteran pharma and biotech executive with 20 years of operations and finance experience joins world-leading team advancing novel targeted protein enhancement modality Watertown, MA, May 29, 2024 – Entact Bio, the pioneer of precision medicines that enhance the function of beneficial proteins, today announced the appo...